Gregory W Schultz

US Patent:

6713074, Mar 30, 2004

Filed:

Jun 29, 2001

Appl. No.:

09/896566

Inventors:

David S. Lerner - Boca Raton FL
Gregory Schultz - Gainesville FL

Assignee:

Quick Med Technologies Inc. - Gainesville FL
University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A61K 700

US Classification:

424401, 424 59, 514 23, 514 24, 514 25, 514 26, 514 33, 514182

Abstract:

The cosmetic topical formulation of this invention is directed toward diminishing skin wrinkling, fine line, improving skin tone, and combinations thereof. Preferably, the topical formulation contains a matrix metalloproteinase inhibitor, MMPI, and advantageously includes a natural estrogen, e. g. , a true estrogen compound, such as 17-beta estradiol, or an estrogen-like steroid, (such as various phytoestrogens found in herbal preparations), as opposed to a synthetic estrogen. Other forms of the cosmetic topical formulation of this invention include combinations of synthetic estrogen and MMP inhibitor. Exemplary synthetic estrogens include, but are not limited to, ethinyl estradiol and clomiphine citrate. The cosmetic topical formulation is safe and effective diminishing wrinkling, and improving skin tone. Certain compositions of this invention are useful for minimizing photodamage to skin, while in other embodiments, the composition according to this invention is useful to prevent or minimize the adverse effects on skin induced by cigarette smoking.

US Patent:

20030083321, May 1, 2003

Filed:

Sep 25, 2002

Appl. No.:

10/256215

Inventors:

David Lerner - Boca Raton FL, US
Gregory Schultz - Gainesville FL, US

International Classification:

A61K031/56

US Classification:

514/171000

Abstract:

The invention pertains to compositions and methods to treat the adverse effects of mustard chemicals and other toxic compounds, such as chemical warfare agents, exposure to which normally induces vesicating type response in mammals. In a rodent eye model at fixed concentrations of such a vesicant, compositions comprising (a) a matrix metalloproteinase inhibitor, MMPI, and (b) a protease inhibitor, PI, such as a serine protease inhibitor, SPI, a significant reduction in morbidity is achieved with increased concentrations of the compositions of this invention, as compared with an MMPI inhibitor alone or vehicle alone. Furthermore, compositions comprising the MMPI, the SPI, and in addition, an anti-inflammatory compound, in a vehicle appropriate to the type of tissue damage to be protected against from vesicant exposure, achieves both reduction in total tissue damage and inflammation, as compared with anti-inflammatory composition alone. Chemicals having more than one property, such as MMPI and AIA properties, are also disclosed. Certain combinations disclosed are applied to treat injuries due to acids and bases.